Theorem Clinical Research Joins MedNet Solutions' iMedNet Partner Program - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Theorem Clinical Research Joins MedNet Solutions' iMedNet Partner Program Theorem Selects iMedNet" EDC as Their eClinical Solution of Choice for Medical Device & Diagnostics Research Initiatives


Theorem Clinical Research Joins MedNet Solutions' iMedNet Partner Program

Theorem Selects iMedNet™ EDC as Their eClinical Solution of Choice for Medical Device & Diagnostics Research Initiatives

PR Newswire

MINNETONKA, Minn., April 29, 2014 /PRNewswire/ -- MedNet Solutions, a global life sciences technology company specializing in eClinical technology systems, is pleased to welcome Theorem Clinical Research into the iMedNet Partner Program.  Theorem, one of the industry's leading contract research organizations, provides comprehensive clinical research and development services to customers around the world. 

"The partnership with MedNet supports Theorem's commitment to serve as a leader in CRO services to the medical device and diagnostic community.  Theorem looks to extend the experience and quality that ensure our customers' medical device product success," said Lee Spurgin, PhD, Senior Vice President and General Manager for Medical Device & Diagnostic Development at Theorem.

"MedNet is extremely pleased to be partnering with Theorem, an innovative and highly respected CRO with a truly global presence," noted John M. (Rob) Robertson, President and CEO of MedNet Solutions.  "Our significant technical experience in the medical device arena meshes perfectly with Theorem's deep therapeutic and device research expertise.  We're looking forward to working closely with Theorem for many years to come." 

Stay in touch with MedNet:

About Theorem Clinical Research

Theorem Clinical Research Inc. is a leading midsized provider of comprehensive clinical research and development services with offices in more than 30 countries and a customer base comprised of some of the world's top pharmaceutical, biotech and medical device companies. As a forerunner in medical device and drug-device combination trials with notable capabilities in pharmaceuticals and biologics, Theorem offers deep expertise in a broad range of therapeutic areas and in all phases of development. With some of the industry's top scientists and most advanced clinical analytics capabilities, Theorem ensures smooth-running, successful trials. For the full-service, right-size global research partner, don't think twice. THINK THEOREM.  For more information, please visit www.theoremclinical.com.

About MedNet Solutions

MedNet Solutions is a leading healthcare technology company specializing in electronic data capture (EDC) and clinical trial management systems (CTMS) designed for the global life sciences market.  MedNet delivers proven, flexible and easy-to-use web-based eClinical solutions that effectively support clinical studies, registries and investigator initiated trials of all types and sizes.  Since 2001, MedNet has successfully supported pharmaceutical, medical device, biotechnology and Contract Research Organizations (CROs) on clinical research conducted around the world.  These companies trust MedNet to consistently deliver the technology innovation, experience and reliability they need for success.  For more information, please visit www.mednetstudy.com.

MedNet Contact Information
Dirk H. Nelson
Director of Marketing
MedNet Solutions
110 Cheshire Lane, Suite 300
Minnetonka, MN  55305 
USA
763.258.2735
contact@mednetstudy.com

Theorem Contact Information           
Lea Studer
308.237.5567
lea@scorrmarketing.com

SOURCE MedNet Solutions

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here